JP2015522045A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522045A5
JP2015522045A5 JP2015520844A JP2015520844A JP2015522045A5 JP 2015522045 A5 JP2015522045 A5 JP 2015522045A5 JP 2015520844 A JP2015520844 A JP 2015520844A JP 2015520844 A JP2015520844 A JP 2015520844A JP 2015522045 A5 JP2015522045 A5 JP 2015522045A5
Authority
JP
Japan
Prior art keywords
compounds
formula
compound represented
following groups
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522045A (ja
JP6189434B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/001950 external-priority patent/WO2014008992A1/en
Publication of JP2015522045A publication Critical patent/JP2015522045A/ja
Publication of JP2015522045A5 publication Critical patent/JP2015522045A5/ja
Application granted granted Critical
Publication of JP6189434B2 publication Critical patent/JP6189434B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520844A 2012-07-10 2013-07-03 ピリミジンピラゾリル誘導体 Active JP6189434B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261669843P 2012-07-10 2012-07-10
EP12175660 2012-07-10
EP12175660.5 2012-07-10
US61/669,843 2012-07-10
PCT/EP2013/001950 WO2014008992A1 (en) 2012-07-10 2013-07-03 Pyrimidine pyrazolyl derivatives

Publications (3)

Publication Number Publication Date
JP2015522045A JP2015522045A (ja) 2015-08-03
JP2015522045A5 true JP2015522045A5 (enExample) 2017-07-06
JP6189434B2 JP6189434B2 (ja) 2017-08-30

Family

ID=49915426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520844A Active JP6189434B2 (ja) 2012-07-10 2013-07-03 ピリミジンピラゾリル誘導体

Country Status (18)

Country Link
US (1) US9216991B2 (enExample)
EP (1) EP2872501B1 (enExample)
JP (1) JP6189434B2 (enExample)
KR (1) KR20150033716A (enExample)
CN (1) CN104662014B (enExample)
AU (1) AU2013289615B2 (enExample)
BR (1) BR112015000399A2 (enExample)
CA (1) CA2878621C (enExample)
DK (1) DK2872501T3 (enExample)
ES (1) ES2589558T3 (enExample)
HU (1) HUE029559T2 (enExample)
IL (1) IL236542B (enExample)
MX (1) MX2015000129A (enExample)
PT (1) PT2872501T (enExample)
RU (1) RU2015104123A (enExample)
SG (1) SG11201500005SA (enExample)
WO (1) WO2014008992A1 (enExample)
ZA (1) ZA201500917B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2933107C (en) * 2014-01-09 2022-06-21 Merck Patent Gmbh Pyrimidine pyrazolyl derivatives and their use as irak inhibitors
EP3129023B1 (en) 2014-03-27 2021-02-24 Eicosis, LLC Potent soluble epoxide hydrolase inhibitors
PT3221306T (pt) * 2014-11-20 2020-02-19 Merck Patent Gmbh Compostos de heteroarilo como inibidores de irak e utilização dos mesmos
CN105153211B (zh) * 2015-09-22 2017-02-01 上海晋鲁医药科技有限公司 一种合成1‑(N‑Boc‑4‑哌啶)‑4‑吡唑硼酸频哪醇酯的方法
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
MX387359B (es) 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
CN106967073A (zh) * 2017-04-24 2017-07-21 刘双伟 一种治疗类风湿性关节炎的药物
CN108164536A (zh) * 2017-05-08 2018-06-15 刘双伟 一种用于治疗类风湿性关节炎的新的化合物的合成方法
EP3684365A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND USES OF SUCH
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
TWI898556B (zh) 2018-07-13 2025-09-21 美商基利科學股份有限公司 吡咯并[1,2-b]嗒衍生物
JP7186874B2 (ja) * 2018-10-26 2022-12-09 アーリーン ファーマシューティカルズ エルエルシー ピラゾリル化合物およびその使用方法
SG11202105424PA (en) 2018-11-30 2021-06-29 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021099406A1 (en) * 2019-11-20 2021-05-27 F. Hoffmann-La Roche Ag Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
CN110950839B (zh) * 2019-12-17 2023-04-14 蚌埠中实化学技术有限公司 4-(4-卤代-1h-吡唑-1-基)哌啶-1-羧酸叔丁酯的制备方法
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
MX2022007576A (es) 2019-12-17 2022-09-23 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
AU2021413371A1 (en) 2020-12-30 2023-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN116670142A (zh) * 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
AU2022220043A1 (en) 2021-02-15 2023-08-31 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
CN118302168A (zh) 2021-10-29 2024-07-05 凯麦拉医疗公司 Irak4降解剂和其制备
EP4472967A2 (en) 2022-01-31 2024-12-11 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2024011116A2 (en) * 2022-07-07 2024-01-11 Dana-Farber Cancer Institute, Inc. Potent and selective irreversible inhibitors of irak1
CN115490621B (zh) * 2022-10-14 2024-06-21 浙江工业大学 一种碘代双环[1.1.1]戊烷衍生物的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
CA2432799C (en) * 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE102008025750A1 (de) * 2008-05-29 2009-12-03 Merck Patent Gmbh Dihydropyrazolderivate
DE102008062825A1 (de) * 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
WO2010100144A1 (en) 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
CA2757671A1 (en) * 2009-04-03 2010-10-07 Cellzome Ag Methods for the identification of kinase interacting molecules and for the purification of kinase proteins
DE102009033208A1 (de) * 2009-07-15 2011-01-20 Merck Patent Gmbh Aminopyridinderivate
EP2515657A4 (en) * 2009-12-21 2013-07-03 Merck Sharp & Dohme Tyrosine kinase inhibitor
CA2802641C (en) * 2010-07-13 2019-03-12 Nidhi Arora Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators

Similar Documents

Publication Publication Date Title
JP2015522045A5 (enExample)
JP2011105738A5 (enExample)
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
JP2013214010A5 (enExample)
JP2015125255A5 (enExample)
EA201600091A1 (ru) 4-членные кольцевые карбоксамиды, применяемые в качестве нематоцидов
JP2013531018A5 (enExample)
JP2014235432A5 (enExample)
JP2014211586A5 (enExample)
JP2012111758A5 (enExample)
JP2013212124A5 (enExample)
JP2012204203A5 (enExample)
JP2015501646A5 (enExample)
JP2013532130A5 (enExample)
JP2015518492A5 (enExample)
JP2015158628A5 (enExample)
JP2015173751A5 (enExample)
WO2015022265A3 (en) Cyclobutyl carboxamides as nematicides
JP2015537124A5 (enExample)
JP2015042663A5 (enExample)
JP2013531183A5 (enExample)
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
JP2012250569A5 (enExample)
RU2011118463A (ru) Ароматические блок-сополиэфиркетоны
JP2014508179A5 (enExample)